丹七软胶囊联合曲美他嗪治疗冠心病心绞痛的临床效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (964 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary artery heart disease. Methods One hundred and four patients with angina pectoris of coronary heart disease admitted to Northern Jiangsu People’s Hospital from March 2017 to May 2019 were selected and divided into control group and observation group by random number table method, with 52 cases in each group. The control group was treated with Trimetazidine, while the observation group was treated with Danqi Soft Capsules on the basis of control group. Both groups were treated for 4 weeks. The clinical efficacy was evaluated after treatment. The visual analogue scale (VAS) of angina pectoris, duration and attack times of angina pectoris, lactic acid dehydrogenase (LDH), aspartate aminotransferase (AST), creatine kinase isoenzyme (CK-MB), nitric oxide (NO), endothelin-1 (ET-1), fibrinogen (FIB) and prothrombin time (PT) were compared between the two groups. The adverse reactions during treatment were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group (P ＜ 0.05). After treatment, VAS in the two groups was lower than that before treatment, the duration was shorter than that before treatment, and the attack times of angina pectoris were less than that before treatment. Moreover, VAS in the observation group was lower than that in the control group, the duration was shorter than that in the control group, and the attack times were less than that in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the LDH, AST, CK-MB, ET-1 and FIB levels in the two groups were lower than those before treatment (P ＜ 0.05), and the LDH, AST, CK-MB, ET-1 and FIB levels in the observation group were lower than those in the control group (P ＜ 0.05). The NO and PT levels in the two groups were significantly higher than those before treatment (P ＜ 0.05), and NO and PT levels in the observation group were higher than those in the control group (P ＜ 0.05). There was no significant difference of the incidence of adverse reactions between the two groups during the treatment (P ＞ 0.05). Conclusion Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary heart disease can obviously alleviate the degree of angina pectoris pain, reduce the duration and attack times, lower the LDH, AST, CK-MB, ET-1 and FIB levels, increase the NO and PT levels, with good clinical effect and no obvious adverse reactions.

Key words： Danqi Soft Capsules Trimetazidine Coronary heart disease Angina pectoris

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FEI Yan PAN Jun

Cite this article:

FEI Yan PAN Jun. Clinical effect of Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary artery heart disease[J]. 中国医药导报, 2020, 17(35): 148-151,155.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I35/148

[1] 全国老年心血管疾病学术研讨会组委会.第五届全国老年心血管疾病学术研讨会暨第十届老年冠心病的诊断和治疗国家级继续教育项目通知[J].中国心血管杂志，2015，20（4）：289-289.
[2] Zhao Y，Yu X，Cao X，et al. Cluster analysis for syndromes of real-world coronary heart disease with angina pectoris [J]. Front Med，2018，12（5）：566-571.
[3] 李勇，肖建强，李文华，等.曲美他嗪对冠心病并左心功能不全患者心功能的影响[J].实用心脑肺血管病杂志，2017，25（2）：115-117.
[4] 姜仲卓.丹七软胶囊对冠心病心绞痛发作及血管的保护作用研究[J].河北中医，2016，38（6）：916-920.
[5] 颜红兵.临床冠心病诊断与治疗指南[M].北京：人民卫生出版社，2010：14-17.
[6] 阎雪.个体化全方位护理干预对不稳定型心绞痛伴情绪障碍患者的影响[J].临床心身疾病杂志，2016（1）：152-153.
[7] 林镇坤.芪参胶囊治疗冠心病心绞痛的临床疗效[J].中国现代药物应用，2016，10（24）：3-4.
[8] Wirtz PH，von K?覿nel R. Psychological Stress，Inflammation，and Coronary Heart Disease [J]. Curr Cardiol Rep，2017，19（11）：111.
[9] 周淑妮.麝香心脑乐胶囊联合美托洛尔治疗冠心病心绞痛的临床研究[J].现代药物与临床，2019，34（3）：644-647.
[10] 尹雁，王伟，王俊尧，等.冠心病心绞痛合并高脂血症患者气滞血瘀痰阻证和气阴两虚痰阻证相关血清蛋白比较分析[J].辽宁中医药大学学报，2018，20（4）：83-85.
[11] 黄素梅，董景珍.冠心病心绞痛影响因素分析及延续护理的应用效果研究[J].现代医学，2020，48（4）：536-539.
[12] 邱丹，王凡，赵涛.丹参多酚酸盐治疗冠心病心绞痛的疗效及其对血液流变学、氧化应激的影响[J].安徽医药，2018，22（1）：147-150.
[13] 江晓波，房汉南，蔡东林.血小板参数及凝血功能与冠心病血瘀证的相关性研究[J].中国处方药，2019，17（9）：152-153.
[14] 沈琳，马文苑.曲美他嗪联合氯吡格雷治疗冠心病心绞痛疗效及对患者心电图、血清超敏C反应蛋白和五聚素3的影响[J].陕西医学杂志，2019，48（6）：794-796.
[15] Rehberger-Likozar A，?譒ebe?觢tjen M. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease [J]. Coron Artery Dis，2015， 26（8）：651-656.
[16] 杨可鑫，于莉，张会永，等.冠心病心绞痛血瘀证证候组成相关文献研究分析[J].辽宁中医药大学学报，2018， 20（11）：70-73.
[17] 梁俊仁.中医在治疗冠心病心绞痛的临床疗效分析[J].中西医结合心血管病电子杂志，2018，6（12）：144.
[18] 王艳霞.丹七软胶囊结合西药治疗老年冠心病心绞痛疗效观察[J].湖北中医药大学学报，2016，18（2）：66-69.
[19] 王云龙，房岐，郑超.丹参化学成分、药理作用及质量控制研究进展[J].中国药业，2020，29（15）：6-10.
[20] 沈海清，肖晶，朱学芳，等.丹七软胶囊联合依达拉奉治疗急性缺血性脑血管病患者的临床观察[J].世界中医药，2018，13（12）：3019-3022，3026.
[21] 金纹宇，朱朋胤，陈洋.丹七软胶囊联合曲美他嗪治疗冠心病心绞痛的临床研究[J].现代药物与临床，2019， 34（5）：1318-1322.
[22] 杨梦，胡志希，李欣春，等.袁肇凯教授治疗冠心病的用药规律探析[J].湖南中医药大学学报，2019，39（10）：1218-1221.
[23] 葛姝君.麝香保心丸联合常规西药治疗冠心病心绞痛患者疗效及对心肌酶谱和心肌肌钙蛋白I水平的影响[J].中国现代药物应用，2018，12（20）：105-106.
[24] 张水青，唐良洪.心肌酶谱检测在急诊检验中的应用价值分析[J].临床医学研究与实践，2017，2（15）：92-93.
[25] 钱春红，余强.理气活血滴丸联合曲美他嗪对冠心病心绞痛患者凝血功能及血清IL-18、SOD、BNP水平的影响[J].现代中西医结合杂志，2018，27（17）：1873-1876.
[26] 畅辉，岳黎明.中西药物联用治疗气阴两虚型冠心病心绞痛75例[J].西部中医药，2019，32（8）：98-100.
[27] 杨崇贵.丹红注射液联合麝香保心丸治疗心血瘀阻型冠心病心绞痛的临床效果及对患者血管内皮功能和炎症因子的影响[J].世界中西医结合杂志，2017，12（11）：1576-1579.